Our Expert in Spain

GOLD

Jordi Casas

GOLD

Selling a Spanish Tech or Life‑sciences Company to a Foreign Buyer in 2026: a Seller’s Playbook

By Global Law Experts

– posted 2 hours ago

Selling a company Spain-based to a foreign buyer in 2026 has become both a bigger opportunity and a more demanding exercise than at any point in the last decade. Capital is flowing back into Spanish M&A, buyers are competing for quality assets, and yet cross-border screening, data protection and due diligence intensity have all tightened at the same time. For founders, boards, CFOs and corporate counsel of Spanish tech and life-sciences companies, that combination means one thing: preparation now decides price, speed and certainty later.

This playbook sets out exactly what a seller should do, from the first 90 days of corporate housekeeping through deal structure, regulatory screening, due diligence and closing, so you enter the process in control rather than reacting to a buyer’s agenda.

Search-intent summary

Who this is for: founders, boards, CFOs and corporate counsel of Spanish tech or life-sciences companies evaluating a sale to a foreign buyer in 2026. What you get: an actionable readiness checklist, a share-versus-asset decision table, a regulatory screening flow, tax flags, due diligence tactics and a 90-day roadmap to close quickly and reduce price leakage.

Three-line playbook: First, fix your corporate, IP, data and employment house before a buyer sees it. Second, choose the right structure, share or asset sale, and negotiate the SPA levers that protect you. Third, manage regulatory screening and disclosure early so nothing derails the timetable.

1. 2026 market snapshot and what it means for sellers

The backdrop for selling a company Spain-side in 2026 is a market rebound. Deal capital has recovered, and competitive processes are back, good news for well-prepared sellers who can command tension between multiple bidders. But the same buyers running that competition are applying deeper diligence and confronting more regulatory friction than they did a few years ago.

M&A capital and deal activity

Reporting on the Spanish market for 2026 points to a significant recovery in deal value and volume. For sellers, rising aggregate capital signals appetite, but it does not guarantee a premium on any individual deal. Value is captured by companies that present clean, diligence-ready businesses, not by riding the market alone. As one practitioner puts it:

“Sellers who tidy IP, data and employment issues before buyer diligence command better price and fewer post-close claims.”, Jordi Casas

Buyer types active in 2026

Strategic buyers. Corporates seeking technology, talent, regulatory approvals or market access. They value continuity of contracts and staff and often prefer share deals.
Private equity. Financial sponsors focused on cash flows, management retention and clean structures; they push hard on warranties, escrows and earn-outs.
Corporate venture capital. Strategics investing for optionality, sometimes taking minority-to-control positions with staged consideration.

Key regulatory trend, more intense cross-border screening

The single biggest change shaping a cross-border sale Spain-side is the growth of foreign investment screening under the EU framework in Regulation (EU) 2019/452 and Spain’s national screening regime. Tech and life-sciences assets are precisely the sectors regulators watch most closely. Sellers who identify screening triggers early avoid the most common cause of delay and price erosion.

What are the biggest deals expected in 2026? The market press tracks headline transactions, but for sellers the more useful signal is sector activity and buyer type rather than any single named deal. Treat market roundups as context, not as a guide to your own valuation.

2. Pre-sale readiness: corporate housekeeping (the seller’s “first 90 days”)

The most reliable way to prepare a company for sale Spain-side is to run a disciplined 90-day readiness programme before you approach the market. The goal is simple: remove every avoidable point of friction that a buyer could use to reduce price, extend the timetable or expand indemnities. Everything below belongs in a virtual data room organised to a clear index.

Corporate, cap table, authorisations, structure and contracts

Buyers begin with the corporate spine of the company. Get it right first:

Cap table. Reconcile the share register, option grants, convertibles and any side letters. Confirm ownership is clean and free of undocumented promises.
Corporate authorisations. Verify board and shareholder approvals, statutory books and filings are complete under Spanish company law (principally the Ley de Sociedades de Capital) and that filings with the Registro Mercantil are up to date.
Group structure. Map SPVs, dormant entities and intra-group loans. Simplify where possible before diligence.
Material contracts. Collect signed originals, amendments and any documents evidencing change-of-control consents.

IP and licences, the value engine for tech and life-sciences sellers

For anyone looking to sell a tech company Spain-based, IP integrity is where deals are won or lost. Confirm that the company, not founders, contractors or former employees, owns the code, patents and trademarks it relies on.

Ownership chain. Ensure every developer and inventor has assigned rights in writing; check that registrations at the Oficina Española de Patentes y Marcas are current and correctly held.
Inbound and outbound licences. Catalogue licences in and out, noting change-of-control and territorial terms.
Open-source risk. Audit open-source components and their licence obligations; copyleft exposure is a classic diligence red flag for software buyers.

To sell a life sciences company Spain-side, the IP picture extends to regulatory assets. Clinical data, marketing authorisations and manufacturing licences carry their own transfer requirements. Confirm the status and transferability of approvals held with the Agencia Española de Medicamentos y Productos Sanitarios and ensure clinical data governance and consent records are complete and portable.

Commercial contracts, customers, suppliers and change of control

Revenue concentration and contractual fragility are priced by buyers. Identify your top customers and suppliers, then flag any change-of-control, exclusivity, most-favoured-nation or termination-for-convenience clauses. Where key contracts require third-party consent on a sale, plan the consent strategy early rather than discovering it during diligence.

Data and GDPR, mapping, lawful bases and transfers

GDPR does not block a sale, but poor data hygiene delays one. Under the General Data Protection Regulation and Spain’s implementing legislation (Ley Orgánica 3/2018), prepare a data map showing what personal data you hold, on what lawful basis, and how it flows. Documentation the Agencia Española de Protección de Datos expects, records of processing, data processing agreements with processors, and a defensible position on international transfers, should be assembled before the buyer asks. Where the transaction itself involves sharing personal data with the buyer, confirm the lawful basis for that disclosure and whether any obligations arise.

Employment and incentives, contracts, equity and transfer rules

People issues surface late and cost dearly. To prepare a company for sale Spain-side, review employment contracts, collective bargaining coverage, equity and bonus plans, and any change-of-control or acceleration terms. Where a transaction is structured to move employees between entities, business-transfer rules under article 44 of the Estatuto de los Trabajadores and associated consultation obligations may apply and must be planned into the timetable. Lock in key executive retention through incentives that survive the deal, buyers pay for a team that stays.

“The seller who controls the data room controls the narrative. Buyers price uncertainty; documentation removes it.”, Jordi Casas

3. Deal structures, pricing mechanics and tax considerations

Structure is the first strategic decision when selling a company Spain-side. The choice between a share sale and an asset sale drives tax, liability, contract transfer and regulatory workload, and it shapes every subsequent negotiation. The table below is the decision centrepiece.

Share sale vs asset sale, seller comparison

Dimension	Share sale	Asset sale
What is sold	Shares/equity in the target, buyer acquires the entity with its contracts, assets and liabilities	Specific assets and liabilities in an agreed schedule, buyer selectively acquires IP, contracts and assets
Typical buyer	Strategics and PE often prefer share deals for continuity and tax efficiency	Buyers wanting a clean slate to avoid hidden liabilities often prefer asset deals
Tax for seller	Corporate sellers may benefit from the participation exemption on capital gains subject to conditions; individual sellers are taxed on the capital gain under personal income tax rules	Transfer of assets may trigger VAT or transfer taxes and different corporate tax outcomes; a transfer of a going concern may fall outside VAT subject to conditions
Liabilities post-close	Buyer takes on contingent liabilities subject to negotiated indemnities; sellers exit fully but reps and warranties persist	Seller generally retains pre-existing liabilities unless contractually assumed, lower price for risk retention
Transfer of contracts	Many contracts transfer automatically; some consents may still be needed	Assignments/novations often required, third-party consents become a negotiation point
Employees	Employees remain in the same legal entity, potentially simpler; check transfer rules for reorganisations	Employee transfers may trigger business-transfer rules and consultation; more operational work
Regulatory approvals	May be simpler where licences are entity-based; takeover rules can apply to listed targets	Sectoral licences may need assignment/approval; life-sciences notifications may be required
When sellers choose this	When they want a clean exit with continuity of contracts and employees, selling the whole entity	When they must ring-fence liabilities, or the buyer wants selective assets (often at a lower price)

Decision framework, choose one when…

Choose a share sale when the target is a single operating company with clean financials, you want a full exit, buyers value continuity of contracts and staff, shareholder tax treatment is favourable and regulatory consents are manageable.
Choose an asset sale when specific liabilities, legacy litigation, problem contracts, pension deficits, make buyers hesitant, the buyer wants to cherry-pick key assets, or the buyer cannot assume certain regulatory or contractual obligations without significant risk.
Choose a hybrid (share sale with carve-outs or price adjustments) when you need flexibility to balance tax, liability and licensing, common in cross-border deals.

For most tech and life-sciences sellers seeking a clean exit the share sale is the common default, unless identifiable, ring-fenceable liabilities push you toward an asset structure. It typically delivers the exit sellers want and the continuity buyers pay for. The right choice always depends on tax modelling and the specific liability profile.

SPA negotiation levers for sellers

The share purchase agreement is where value is protected or lost. Sellers should focus on:

Price mechanism. Locked-box versus completion accounts; a locked-box gives certainty and can reduce post-close disputes.
Earn-outs. Tie to clear, measurable KPIs and negotiate governance protections so the buyer cannot depress the metrics you must hit.
Escrows. Deferred holdbacks are common; negotiate the amount, release timing and triggers tightly to fit the risk profile.
Reps and warranties. Push for disclosure-based survival, materiality qualifiers and a materiality scrape only where balanced.
Caps and baskets. Negotiate an indemnity cap appropriate to the deal, together with de minimis and basket thresholds that limit small claims.

Cross-border tax flags for sellers

A cross-border sale Spain-side raises tax questions that must be modelled before signing. Confirm capital gains treatment, the availability of any participation exemption and any withholding on payments to a foreign buyer through guidance from the Agencia Estatal de Administración Tributaria. Double tax treaties can eliminate or reduce withholding; VAT can arise on transfers of assets. Where intra-group pricing or post-close arrangements are involved, the OECD transfer pricing and BEPS guidance frames the risk that can affect valuation and post-close obligations. Model the after-tax proceeds early, headline price is not what lands in shareholders’ pockets.

4. Managing due diligence, disclosures and limiting post-close exposure

Due diligence is where a well-run process pays for itself. Sellers who invest in seller due diligence Spain-side control the timeline, set the disclosure narrative and reduce the surface area for warranty claims.

Seller due diligence (vendor DD) scope and timeline

Commission vendor due diligence, legal, financial and tax, before you go to market. A robust vendor DD report surfaces problems while you can still fix them, gives bidders confidence and shortens their confirmatory diligence. Typically this runs in parallel with data-room build during the first weeks of the process, so it is ready when buyers arrive.

Disclosure letter and negotiated disclosure mechanics

The disclosure letter is your primary shield against warranty claims: what is fairly disclosed is generally not something the buyer can later claim on. Adopt a disciplined line-item method, tie disclosures to specific warranties, and negotiate materiality qualifiers. Build disclosure schedules from the data room so every material fact the buyer has seen is captured.

Common seller tactics to limit reps, survival and indemnity caps

Limit survival periods for general warranties, reserving longer tails only for fundamental and tax warranties.
Cap indemnities and negotiate baskets and de minimis thresholds to filter out immaterial claims.
Use warranty and indemnity insurance to bridge the gap between the buyer’s protection appetite and your desire for a clean exit.
Insist on disclosure-based survival so disclosed matters cannot be recycled into claims.

5. Regulatory approvals and screening when selling a company Spain-side

Regulatory clearance is a common cause of delay in a cross-border deal, so it belongs at the front of the plan, not the end. Two workstreams matter most: foreign investment screening and antitrust, plus sector-specific approvals.

Foreign direct investment screening

Under the EU framework in Regulation (EU) 2019/452 and Spain’s national screening rules (found principally in Law 19/2003 on capital movements and its implementing regulations), acquisitions of certain assets or stakes by non-EU/EFTA, and, in defined circumstances, EU/EFTA, buyers require prior authorisation. Follow a simple flow: identify whether the target’s sector or the buyer’s profile triggers screening; assess whether the applicable thresholds are met; if so, prepare and file the notification early; and build the review period and any potential remedies into the timetable. Tech and life-sciences targets are frequently caught, so treat screening as a live risk from day one.

Antitrust and sectoral approvals

Where the deal meets Spanish merger control thresholds, clearance from the Comisión Nacional de los Mercados y la Competencia is required before closing; larger transactions may instead fall within EU merger control before the European Commission. In life sciences, transferring marketing authorisations or manufacturing licences may require notifications to or approvals from the AEMPS. Regulated technology, telecoms assets or products subject to export controls, can carry its own consents. Map every approval, sequence the filings, and make closing conditional on the ones that cannot be waived.

6. Closing, funds flow and post-close integration

Closing is a logistics exercise as much as a legal one. Sellers who plan the mechanics avoid last-minute value leakage.

Typical closing checklist

Conditions precedent satisfied, regulatory approvals, third-party consents and shareholder authorisations confirmed.
Funds flow statement agreed, showing every payment, deduction and account.
Escrow arrangements executed with clear release mechanics and triggers.
Tax positions and documentation in place, with withholding positions confirmed.
Delivery of corporate documents, updated share register, resignations, and transfer instruments (share transfers of Spanish companies are typically formalised before a notary).

Post-close integration and holdbacks

Where consideration is deferred, the seller’s job is not over at signing. Protect earn-outs by agreeing governance rights over the metrics that drive them, secure employee retention through the transition, and plan the orderly transfer of IP, systems and data. Holdbacks and escrows should have unambiguous release conditions so cash is not trapped by vague disputes.

“Deferred consideration is only worth what your governance rights let you protect. Negotiate the earn-out mechanics as hard as the headline price.”, Jordi Casas

7. The 90-day seller roadmap and checklists

Selling a company Spain-side rewards sequencing. Use this roadmap to structure the run-up to market.

Days 1–15: Assemble the deal team, appoint advisers, agree the process (auction or bilateral) and set the data-room index.
Days 16–45: Complete corporate, IP and contract housekeeping; run the GDPR data map; review employment and incentives; commission vendor due diligence.
Days 46–70: Populate the data room, draft disclosure schedules, identify FDI and antitrust triggers, and model after-tax proceeds.
Days 71–90: Finalise marketing materials, agree the process letter and open the market to buyers with a diligence-ready package.

Supporting assets a seller should build include a data-room index, a 90-day readiness checklist, sample disclosure schedule headings and a note of SPA negotiation levers. Prepared correctly, these documents shorten the timetable and reduce price erosion.

Conclusion

Selling a company Spain-side in 2026 is a seller’s opportunity, but only for sellers who prepare. The market has capital and appetite, yet buyers apply deeper diligence and regulators screen tech and life-sciences deals more closely than ever. The winners are companies that fix corporate, IP, data and employment issues before diligence, choose the right structure, negotiate the SPA levers that protect proceeds, and manage FDI and antitrust screening from day one. Follow the 90-day roadmap, control the data room, and you will enter the market on your terms, commanding a stronger price with fewer post-close surprises. Get bespoke seller advice from a specialist M&A adviser in Spain before you go to market.

Need Legal Advice?

This article was produced by Global Law Experts. For specialist advice on this topic, contact Jordi Casas at Osborne Clarke, a member of the Global Law Experts network.

Sources

FAQs

How long does a cross-border sale of a Spanish tech company usually take?

Often around 4–6 months for a competitive process and 6–9 months or more for complex, regulated or FDI-screened deals. The timeline depends on due diligence depth, regulatory filings and the buyer’s internal approvals, early preparation is the biggest lever on speed.

Will GDPR block a sale?

No. GDPR does not block a sale, but it requires a correct lawful basis for transferring personal data to the buyer, such as contract, legitimate interest or consent as appropriate, and controllers and processors must document transfers and, where relevant, sign data processing agreements. In specific circumstances, obligations towards the AEPD may arise.

Do I need to notify Spanish authorities about a foreign buyer?

Possibly. If the sector or asset triggers foreign investment screening, or the transaction meets the thresholds under Spain’s FDI rules or the EU screening framework, prior authorisation may be required. Identify this early to avoid delaying completion.

What are the common warranty claims sellers should expect?

The recurring themes are IP ownership, tax liabilities, employee claims, material contracts, regulatory compliance and, especially in life sciences, product liability. Anticipate these in your disclosure schedules and vendor diligence.

How can sellers reduce post-close indemnity risk when selling a company Spain-side?

Run vendor due diligence, prepare robust disclosure schedules, negotiate caps, baskets and short survival periods, and use escrows or warranty and indemnity insurance to transfer residual risk away from your proceeds.